Good Life Advisors LLC trimmed its position in Iqvia Holdings Inc (NYSE:IQV) by 5.7% during the 1st quarter, Holdings Channel reports. The firm owned 1,624 shares of the medical research company’s stock after selling 99 shares during the period. Good Life Advisors LLC’s holdings in Iqvia were worth $233,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the business. Securian Asset Management Inc boosted its position in Iqvia by 0.5% in the first quarter. Securian Asset Management Inc now owns 16,374 shares of the medical research company’s stock worth $2,355,000 after purchasing an additional 78 shares during the last quarter. Argent Trust Co boosted its position in Iqvia by 0.5% in the fourth quarter. Argent Trust Co now owns 15,406 shares of the medical research company’s stock worth $1,790,000 after purchasing an additional 80 shares during the last quarter. Conning Inc. boosted its position in Iqvia by 3.6% in the first quarter. Conning Inc. now owns 2,600 shares of the medical research company’s stock worth $374,000 after purchasing an additional 90 shares during the last quarter. Utah Retirement Systems boosted its position in Iqvia by 0.3% in the fourth quarter. Utah Retirement Systems now owns 30,360 shares of the medical research company’s stock worth $3,527,000 after purchasing an additional 100 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Iqvia by 1.2% in the first quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the medical research company’s stock worth $1,208,000 after purchasing an additional 100 shares during the last quarter. 94.19% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently weighed in on IQV. Argus lifted their price objective on Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, February 25th. They noted that the move was a valuation call. Wells Fargo & Co lifted their price objective on Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday, February 19th. Barclays lifted their price objective on Iqvia from $160.00 to $167.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Wolfe Research began coverage on Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Finally, UBS Group set a $170.00 price objective on Iqvia and gave the company a “buy” rating in a research report on Friday, February 15th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Iqvia currently has a consensus rating of “Buy” and an average price target of $146.88.

In related news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of Iqvia stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $140.80, for a total transaction of $569,462,784.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ari Bousbib sold 96,000 shares of Iqvia stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $140.96, for a total value of $13,532,160.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,187,753 shares of company stock worth $589,529,674 in the last three months. 6.00% of the stock is owned by corporate insiders.

Shares of IQV opened at $134.44 on Friday. The company has a market cap of $26.52 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.63 and a beta of 0.80. Iqvia Holdings Inc has a 12-month low of $97.64 and a 12-month high of $146.10. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14.

Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.12. The company had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.67 billion. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $1.34 EPS. On average, equities analysts expect that Iqvia Holdings Inc will post 5.88 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.watchlistnews.com/good-life-advisors-llc-reduces-holdings-in-iqvia-holdings-inc-iqv/3020983.html.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: Different Options Trading Strategies

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.